Safety

A WELL DEFINED AND MANAGEABLE SAFETY PROFILE1

*Patients who received one or more doses of study drug for either newly-diagnosed CP CML or were resistant or intolerant to prior therapy with CP, AP, BP CML or Ph+ ALL. 
The data shown include real-world data in addition to safety data from the BFORE trial and Study 200.

 

1% of the overall patient safety population discontinued due to diarrhoea1
 

NO NEW CARDIAC OR VASCULAR SAFETY SIGNALS AT 24 MONTHS IN NEWLY-DIAGNOSED PATIENTS2

 

*Patients who received one or more doses of study drug.

Please refer to the BOSULIF® SmPC for full details of adverse events

AE, adverse event; ALL, acute lymphoblastic leukaemia; ALT, alanine aminotransferase; AP, accelerated phase; AST, aspartate aminotransferase; BP, blast phase; CML, chronic myeloid leukaemia; CP, chronic phase; Ph+, Philadelphia chromosome-positive; SmPC, Summary of Product Characteristics.

References

  1. BOSULIF® (bosutinib) Summary of Product Characteristics.
  2. Cortes et al. Presented at American Society of Clinical Oncology Annual Meeting, 2018; Oral presentation 7002.

PP-BOS-GBR-0908. January 2020